Q1 2027 IOL Chemicals and Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Revenue grew 37% YoY to INR756 crore, with EBITDA up 60.7% and PAT up 89.9%.
- Non-Ibuprofen API portfolio contributed 43% of pharma revenue, up from 36%, with 67% YoY growth.
- Exports increased to 28.5% of revenue, with NMPA approval for Clopidogrel in China expanding market reach.
- Improved capacity utilization (80-95% for most assets) and operational efficiencies drove margin expansion.
- Management guides for 15-20% revenue growth and 14-15% EBITDA margin for FY27, with confidence in sustainability.
- Paracetamol capacity utilization is only 55%, expected to reach 70% by year-end, indicating underutilization.
- Geopolitical uncertainties and supply-chain challenges persist, impacting raw material costs.
- Gross margin declined sequentially due to higher input costs and lag in passing on price increases to customers.
- Dependence on China for DCDA raw material for Metformin remains a supply chain risk.
- Management refrained from upgrading guidance despite strong Q1, citing potential volatility in export volumes and prices.
Ladies and gentlemen, good day and welcome to IOL Chemicals and Pharmaceuticals Limited's Q1 FY27 earnings conference call.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Prachi Ambre from MUFG Investor Relations. Thank you and over to you, ma'am.
Thank you, Uda. Good afternoon, everyone. And welcome to IOL Chemicals and Pharmaceuticals Limited's Q1 FY27 earnings conference call.
Today, on the call, we have Mr. Pardeep Kumar Khanna, Chief Financial Officer; Mr. Abhay Raj Singh, Senior Vice President and Company Secretary; Mr. Kushal Kumar Rana, Director, Works; and Mr. Rakesh Mahajan, Finance Adviser and Strategic Head, to provide insights on the company's operational and financial performance.
Before we begin the call, I would like to give a short disclaimer.
This call may contain some of the forward-looking statements, which are completely based upon our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
